IRWD · Insider Trading
Ironwood Pharmaceuticals, Inc. - Class A
Every open-market purchase and sale reported by IRWD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-17 | Alexander J Denner | Director | A | +3,694 | — |
| 2026-07-22 | Jeffrey Silber | SVP, CMO, Head-Res&Drug | A | +137,036 | — |
| 2026-07-09 | Ronald Silver | PFO & PAO | Sell | −127,890 | −$578.06K |
| 2026-06-17 | Jon R Duane | Director | A | +63,481 | — |
| 2026-06-17 | Mark G Currie | Director | A | +63,481 | — |
| 2026-06-17 | Catherine Moukheibir | Director | A | +63,481 | — |
| 2026-06-17 | Julie McHugh | Director | MIXED | +41,910 | −$80.46K |
| 2026-06-17 | Jay Shepard | Director | A | +63,481 | — |
| 2026-06-17 | Marla L Kessler | Director | A | +63,481 | — |
| 2026-06-17 | Alexander J Denner | Director | A | +67,546 | — |
| 2026-05-21 | Ronald Silver | PFO & PAO | A | +25,000 | — |
| 2026-03-17 | Alexander J Denner | Director | MIXED | −6,726,349 | −$20.53M |
| 2026-03-12 | Minardo John | Chief Legal Officer | A | +136,612 | — |
| 2026-03-12 | Michael Shetzline | SVP, CMO, Head-Res&Drug | A | +136,612 | — |
| 2026-03-12 | Tammi L Gaskins | Chief Commercial Officer | A | +136,612 | — |
| 2026-03-12 | Gregory S. Martini | Chief Financial Officer | A | +136,612 | — |
| 2026-03-12 | Thomas A MCCOURT | Chief Executive Officer | A | +409,836 | — |
| 2026-03-12 | Ronald Silver | Principal Accounting Officer | A | +163,934 | — |
| 2026-02-25 | Thomas A MCCOURT | Chief Executive Officer | Sell | −198,283 | −$739.93K |
| 2026-02-25 | Tammi L Gaskins | Chief Commercial Officer | Sell | −21,526 | −$80.33K |
| 2026-02-25 | Ronald Silver | Principal Accounting Officer | Sell | −24,173 | −$90.21K |
| 2026-02-25 | Minardo John | Chief Legal Officer | Sell | −36,492 | −$136.18K |
| 2026-02-25 | Michael Shetzline | SVP, CMO, Head-Res&Drug | Sell | +1,442 | +$2.94K |
| 2026-02-25 | Gregory S. Martini | Chief Financial Officer | Sell | −21,944 | −$81.89K |
| 2026-01-07 | Ronald Silver | Principal Accounting Officer | Sell | −35,416 | −$162.91K |
| 2025-12-17 | Alexander J Denner | Director | A | +8,356 | — |
| 2025-11-19 | Tammi L Gaskins | Chief Commercial Officer | Sell | −6,016 | −$19.97K |
| 2025-09-17 | Alexander J Denner | Director | A | +11,718 | — |
| 2025-08-13 | Ronald Silver | Principal Accounting Officer | Sell | −2,846 | −$2.39K |
| 2025-08-13 | Tammi L Gaskins | Chief Commercial Officer | Sell | −1,316 | −$1.11K |
| 2025-08-13 | Gregory S. Martini | Chief Financial Officer | Sell | −1,265 | −$1.06K |
| 2025-08-13 | Minardo John | Chief Legal Officer | Sell | −7,754 | −$6.51K |
| 2025-06-17 | Alexander J Denner | Director | A | +48,386 | — |
| 2025-06-12 | Jon R Duane | Director | A | +45,000 | — |
| 2025-06-12 | Catherine Moukheibir | Director | A | +45,000 | — |
| 2025-06-12 | Marla L Kessler | Director | A | +45,000 | — |
| 2025-06-12 | Mark G Currie | Director | A | +45,000 | — |
| 2025-06-12 | Jay Shepard | Director | A | +45,000 | — |
| 2025-06-12 | Andrew Dreyfus | Director | A | +45,000 | — |
| 2025-06-12 | Sarissa Capital Management LP | 10%+ Owner | A | +90,000 | — |
| 2025-06-12 | Julie McHugh | Director | A | +45,000 | — |
| 2025-05-20 | Tammi L Gaskins | Chief Commercial Officer | Sell | −2,563 | −$1.49K |
| 2025-05-20 | Thomas A MCCOURT | Chief Executive Officer | MIXED | +526,647 | −$7.74K |
| 2025-04-04 | Alexander J Denner | Director | A | +20,832 | — |
| 2025-02-12 | Thomas A MCCOURT | Chief Executive Officer | Sell | −139,064 | −$244.75K |
| 2025-02-12 | Gregory S. Martini | Chief Financial Officer | Sell | −12,052 | −$21.21K |
| 2025-02-12 | Michael Shetzline | SVP, CMO, Head-Res&Drug | MIXED | +92,064 | −$72.63K |
| 2025-02-12 | Ronald Silver | Principal Accounting Officer | Sell | −12,048 | −$21.20K |
| 2025-02-12 | Minardo John | Chief Legal Officer | MIXED | +83,284 | −$68.53K |
| 2025-01-29 | Ronald Silver | Principal Accounting Officer | A | +133,333 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sarissa Capital Management LP | 10%+ Owner | 16,601,769 | $58.94M |
| Alexander J Denner | Director | 9,521,984 | $33.80M |
| Thomas A MCCOURT | Chief Executive Officer | 1,898,838 | $6.74M |
| Mark G Currie | Director | 676,900 | $2.40M |
| Michael Shetzline | SVP, CMO, Head-Res&Drug | 658,037 | $2.34M |
| Minardo John | Chief Legal Officer | 500,498 | $1.78M |
| Tammi L Gaskins | Chief Commercial Officer | 350,350 | $1.24M |
| Ronald Silver | PFO & PAO | 313,680 | $1.11M |
| Sravan Kumar Emany | SVP, COO and CFO | 309,572 | $1.10M |
| Gregory S. Martini | Chief Financial Officer | 297,213 | $1.06M |
| Andrew Davis | SVP, Chief Business Officer | 284,685 | $1.01M |
| Jon R Duane | Director | 253,820 | $901.06K |
| Julie McHugh | Director | 250,749 | $890.16K |
| Jay Shepard | Director | 235,036 | $834.38K |
| Marla L Kessler | Director | 229,364 | $814.24K |
| Andrew Dreyfus | Director | 228,313 | $810.51K |
| Catherine Moukheibir | Director | 181,425 | $644.06K |
| Jeffrey Silber | SVP, CMO, Head-Res&Drug | 137,036 | $486.48K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IRWD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.